Wall Street analyst estimates for Protagonist Therapeutics, Inc. (PTGX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Consensus price target
$177.25 (+27 % vs price $139.37)
between $165.00 and $190.00 · 10 targets published in the last quarter
Closing price, Nov 2
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $550M | $528M – $581M | $4.69 | 9 |
| 2027E | $205M | $104M – $303M | -$0.39 | 9 |
| 2028E | $388M | $102M – $866M | $2.23 | 8 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 26 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 26 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $2.50 | ||
| 2026-08-05 | $2.29 | $2.23 | +2.7% |
| 2026-05-05 | $0.05 | $-0.65 | +107.7% |
| 2026-02-25 | $-0.69 | $-0.53 | -30.2% |
| 2025-11-06 | $-0.62 | $-0.59 | -5.1% |
| 2025-08-06 | $-0.55 | $-0.53 | -3.8% |
| 2025-05-06 | $-0.19 | $-0.50 | +62.0% |
| 2025-02-21 | $1.98 | $0.06 | +3200.0% |
Valuation Ratios
| P/E Ratio | 134.83 |
| Price / Book | 10.92 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $20.1M | $30.9M | $231,000 | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| Cost of Revenue | $317,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.2M |
| Gross Profit | -$317,000 | $20.1M | $30.9M | $231,000 | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $44.8M |
| Research & Development | $25.7M | $46.2M | $59.5M | $65.0M | $76.0M | $126.0M | $126.2M | $120.2M | $138.1M | $159.3M |
| Selling, General & Admin | $7.0M | $11.8M | $13.7M | $15.7M | $18.6M | $27.2M | $31.7M | $33.5M | $43.5M | $44.9M |
| Operating Expenses | $32.7M | $58.0M | $73.2M | $80.8M | $93.1M | $153.2M | $158.0M | $153.7M | $181.6M | $202.9M |
| Operating Income | -$32.7M | -$37.9M | -$42.3M | -$80.5M | -$64.5M | -$125.8M | -$131.4M | -$93.7M | $252.8M | -$158.1M |
| EBITDA | -$32.3M | -$36.6M | -$39.2M | -$75.2M | -$61.8M | -$122.8M | -$124.0M | -$75.6M | $282.4M | -$128.0M |
| Interest Expense | 0 | 0 | 0 | $169,000 | $598,000 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$37.2M | -$37.0M | -$39.7M | -$77.9M | -$64.8M | -$125.6M | -$127.4M | -$79.0M | $279.4M | -$129.3M |
| Income Tax | 0 | 0 | -$799,000 | -$691,000 | $1.3M | 0 | 0 | 0 | $4.2M | $838,000 |
| Net Income | -$37.2M | -$37.0M | -$38.9M | -$77.2M | -$66.2M | -$125.6M | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| EPS | -$5.72 | -$2.09 | -$1.74 | -$2.98 | -$1.92 | -$2.65 | -$2.52 | -$1.39 | $4.47 | -$2.05 |
| EPS (Diluted) | -$5.72 | -$2.09 | -$1.74 | -$2.98 | -$1.92 | -$2.65 | -$2.52 | -$1.39 | $4.23 | -$2.05 |
| Shares Outstanding (Diluted) | 6.5 M | 17.7 M | 22.4 M | 25.9 M | 34.4 M | 46.3 M | 49.0 M | 56.8 M | 65.1 M | 63.6 M |
Price
| Price | $139.37 (closing price, November 2, 2026) |
| Market Cap | $9.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: IMVT · SYRE · IRON · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks